tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

GB:AZN Stock Latest News

AIM announces planned milestones in Phase 2 trial of Ampligen, Durvalumab
The FlyAIM announces planned milestones in Phase 2 trial of Ampligen, Durvalumab
16h ago
AIM
AZN
AstraZeneca’s treatment of follicular lymphoma granted FDA orphan designation
PremiumThe Fly
AstraZeneca’s treatment of follicular lymphoma granted FDA orphan designation
4d ago
AZN
AstraZeneca announces FDA approval for Calquence combination
PremiumThe Fly
AstraZeneca announces FDA approval for Calquence combination
4d ago
AZN
AstraZeneca’s Calquence with venetoclax approved in U.S. by FDA
PremiumThe Fly
AstraZeneca’s Calquence with venetoclax approved in U.S. by FDA
4d ago
AZN
AstraZeneca wins U.S. nod for first fixed-duration all-oral CLL combo
PremiumCompany Announcements
AstraZeneca wins U.S. nod for first fixed-duration all-oral CLL combo
4d ago
AZN
AstraZeneca Targets Hidden COPD Burden in Heart Clinics: What Investors Should Watch
PremiumCompany AnnouncementsAstraZeneca Targets Hidden COPD Burden in Heart Clinics: What Investors Should Watch
5d ago
AZN
AstraZeneca marketing authorization application for Enhertu validated by EMA
Premium
The Fly
AstraZeneca marketing authorization application for Enhertu validated by EMA
5d ago
AZN
FDA to begin requiring on clinical trial
Premium
The Fly
FDA to begin requiring on clinical trial
5d ago
AZN
BMY
FDA to begin requiring one clinical trial in drug approvals
PremiumThe Fly
FDA to begin requiring one clinical trial in drug approvals
5d ago
AZN
BMY
AstraZeneca publishes KALOS, LOGOS trial data
PremiumThe Fly
AstraZeneca publishes KALOS, LOGOS trial data
11d ago
AZN
AstraZeneca announces Phase III KALOS, LOGOS trials published on Breztri
PremiumThe Fly
AstraZeneca announces Phase III KALOS, LOGOS trials published on Breztri
11d ago
AZN
Midday Fly By: January payrolls jump, Ford reports mixed Q4
PremiumThe Fly
Midday Fly By: January payrolls jump, Ford reports mixed Q4
13d ago
F
PM
AstraZeneca Earnings Call Highlights Growth And Pipeline
PremiumCompany AnnouncementsAstraZeneca Earnings Call Highlights Growth And Pipeline
13d ago
AZN
Midday Fly By: Coca-Cola reports Q4 beat, BP suspends buyback
Premium
The Fly
Midday Fly By: Coca-Cola reports Q4 beat, BP suspends buyback
14d ago
U
BP
AstraZeneca sees FY26 core EPS up low double-digit percentage
Premium
The Fly
AstraZeneca sees FY26 core EPS up low double-digit percentage
14d ago
AZN
AstraZeneca reports Q4 core EPS $2.12 vs. $2.09 last year
PremiumThe Fly
AstraZeneca reports Q4 core EPS $2.12 vs. $2.09 last year
14d ago
AZN
AstraZeneca: Buy Rating Backed by Solid Execution, Attractive Valuation, and Late‑Stage Pipeline Upside
PremiumRatings
AstraZeneca: Buy Rating Backed by Solid Execution, Attractive Valuation, and Late‑Stage Pipeline Upside
14d ago
AZN
AstraZeneca sees FY26 core EPS increasing by low double-digit percentage
PremiumThe Fly
AstraZeneca sees FY26 core EPS increasing by low double-digit percentage
14d ago
AZN
AstraZeneca reports Q4 core EPS $2.12, down 2% at CER
PremiumThe Fly
AstraZeneca reports Q4 core EPS $2.12, down 2% at CER
14d ago
AZN
AstraZeneca lifts earnings, advances pipeline and issues upbeat 2026 outlook
PremiumCompany AnnouncementsAstraZeneca lifts earnings, advances pipeline and issues upbeat 2026 outlook
14d ago
AZN
AstraZeneca price target raised to 11,500 GBp from 11,000 GBp at Deutsche Bank
Premium
The Fly
AstraZeneca price target raised to 11,500 GBp from 11,000 GBp at Deutsche Bank
17d ago
AZN
Trump Trade: Argentina says U.S. to cut hundreds of tariffs
Premium
The Fly
Trump Trade: Argentina says U.S. to cut hundreds of tariffs
18d ago
BA
AZN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >